AMRX analyst estimates
Amneal (AMRX) analyst ratings, the average price target and its range, and every firm's latest call.
AMRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Goldman Sachs | Amneal Pharmaceuticals price target raised to $24 from $21 at Goldman Sachs | $24.00 |
| Sep 23, 2026 | Oppenheimer | Amneal Pharmaceuticals initiated with an Outperform at Oppenheimer | $27.00 |
| Sep 17, 2026 | Barclays | Amneal Pharmaceuticals price target raised to $20 from $16 at Barclays | $20.00 |
| Sep 9, 2026 | Leerink Partners | Amneal Pharmaceuticals initiated with an Outperform at Leerink | $23.00 |
| Aug 3, 2026 | UBS | Amneal Pharmaceuticals price target raised to $25 from $23 at UBS | $25.00 |
| Jul 31, 2026 | Goldman Sachs | Amneal Pharmaceuticals price target raised to $21 from $19 at Goldman Sachs | $21.00 |
| Jul 15, 2026 | UBS | Amneal Pharmaceuticals price target raised to $23 from $19 at UBS | $23.00 |
| May 20, 2026 | Barclays | Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays | $16.00 |
| Apr 17, 2026 | UBS | Amneal Pharmaceuticals initiated with a Buy at UBS | $19.00 |
| Mar 2, 2026 | Truist Financial | Amneal Pharmaceuticals (AMRX) PT Raised to $17; Truist: 'Stock pullback a great entry point' | $17.00 |
| Jan 7, 2026 | Truist Financial | Amneal Pharmaceuticals price target raised to $15 from $14 at Truist | $15.00 |
| Dec 8, 2025 | Barclays | Amneal Pharmaceuticals initiated with an Overweight at Barclays | $15.00 |
| Mar 3, 2025 | Barclays | Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays | $11.00 |
| Nov 11, 2024 | Piper Sandler | Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler | $11.00 |
| Oct 2, 2024 | Truist Financial | Amneal Pharmaceuticals price target raised to $12 from $10 at Truist | $12.00 |
- 6 firms rate AMRX: 6 buy, 0 hold, 0 sell.
- The average price target is $23.80 from 5 analysts, from $20.00 to $27.00.
Updated 2026-11-02 23:59 UTC